GSK's RSV Vaccine Offers Protection Over Three Seasons, Study Shows
By Mauro Orru
GSK said data from a late-phase study showed that its respiratory syncytial virus vaccine, Arexvy, granted protection over three full RSV seasons.
The British pharmaceutical giant said a phase 3 trial showed Arexvy's efficacy after a single dose over three full RSV seasons stood at 62.9% against respiratory syncytial virus-lower respiratory tract disease and at 67.4% against severe RSV-LRTD compared to a placebo. The company said the vaccine's efficacy in the third season was 48% for RSV-LRTD.
The study focused on the efficacy of a single dose of Arexvy against lower respiratory tract disease caused by RSV in adults aged 60 years and older.
Arexvy was launched in the third quarter of last year.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
October 08, 2024 07:19 ET (11:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy During Q4
-
Markets Brief: Is 16% a Good Return?
-
Should Emerging-Markets Stocks Stand Alone in Your Portfolio?
-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
2 Dirt Cheap Stocks to Buy If You Want to Take a Flier
-
New 4-Star Stocks
-
3 Dividend Stocks for October 2024
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
United States